Clinical trial
Treatment and Survival Continuation Study of Atamestane Plus Toremifene vs…
NCT00267553 · Intarcia Therapeutics, Industry · Terminated
Key facts
| NCT number | NCT00267553 |
|---|---|
| Title | Treatment and Survival Continuation Study of Atamestane Plus Toremifene vs Letrozole in Advanced Breast Cancer |
| Official title | Open Label Treatment and Survival Continuation Study of Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer |
| Lead sponsor | Intarcia Therapeutics, Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Breast Neoplasms, Neoplasms, Hormone-Dependent |
| Intervention type | Drug |
| Interventions | Atamestane, toremifene, letrozole |
| Enrollment | 200 |
| Start date | Nov 1, 2005 |
| Completion | Jun 1, 2006 |
| First posted | Dec 21, 2005 |
| Last update posted | Sep 10, 2007 |
| Countries | Canada, Russia, Ukraine, United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: